A new drug for pancreatic cancer has been shown to double patient survival after chemotherapy. This significant breakthrough brings hope for one of the most lethal forms of cancer, which is frequently diagnosed at a late stage.
The European Medicines Agency is accelerating the authorization process for this treatment, recognizing the urgency of new therapeutic options for patients with this disease.
Pancreatic cancer is known for its low survival rate, with many diagnoses occurring at advanced stages of the disease, which limits the available treatment options.




